Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia
- PMID: 1372772
- DOI: 10.1007/BF00296526
Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia
Abstract
A rat model for benign prostatic hyperplasia in man (BPH) was investigated. Citral treatment of male Copenhagen rats for 4 months via the transdermal route resulted in a marked hyperplasia of glandular epithelium and interglandular stroma in the ventral prostate. Despite the cellular hyperplasia there was not a significant increase in prostate weight. Investigations of the mechanism of action of citral showed that application of citral directly to the vagina in female, ovariectomized rats resulted in an increased proliferation of vaginal epithelium and a significant increase in the BrdUrd incorporation in vaginal epithelial cells, in short a similar effect to that of estrogen application. In an in vitro assay citral proved to inhibit estrogen binding to estrogen receptors, while no such inhibition was observed with testosterone for androgen receptors. These observations together with the estrogen implication in the BPH and the reported incidence of gynecomastia following exposure to geraniol, a precursor of citral, strongly suggest that the prostatic hyperplasia-inducing capacity of citral may be due to its estrogenic action.
Similar articles
-
Citral and testosterone interactions in inducing benign and atypical prostatic hyperplasia in rats.Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996 Oct;115(2):169-77. doi: 10.1016/s0742-8413(96)00057-6. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996. PMID: 9568365
-
Early stages of the pathogenesis of rat ventral prostate hyperplasia induced by citral.Eur Urol. 1986;12(3):195-200. doi: 10.1159/000472615. Eur Urol. 1986. PMID: 2423338
-
Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains.J Androl. 1994 Jul-Aug;15(4):287-97. J Androl. 1994. PMID: 7527017
-
Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):565-72. doi: 10.1016/0960-0760(93)90260-4. J Steroid Biochem Mol Biol. 1993. PMID: 7682838 Review.
-
Clinical and experimental studies of benign prostatic hyperplasia.Urol Clin North Am. 1990 Aug;17(3):461-75. Urol Clin North Am. 1990. PMID: 1695775 Review.
Cited by
-
Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors.Ther Adv Med Oncol. 2018 Apr 2;10:1758835918766189. doi: 10.1177/1758835918766189. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29636827 Free PMC article.
-
Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90.Toxicol Rep. 2018 Apr 5;5:489-496. doi: 10.1016/j.toxrep.2018.03.014. eCollection 2018. Toxicol Rep. 2018. PMID: 29854620 Free PMC article.
-
Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats.J Inflamm (Lond). 2011 Dec 23;8(1):40. doi: 10.1186/1476-9255-8-40. J Inflamm (Lond). 2011. PMID: 22195697 Free PMC article.
-
Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling.Hormones (Athens). 2010 Jul-Sep;9(3):191-205. doi: 10.14310/horm.2002.1270. Hormones (Athens). 2010. PMID: 20688617 Free PMC article. Review. No abstract available.
-
Prediction of rodent carcinogenicity using the DEREK system for 30 chemicals currently being tested by the National Toxicology Program. The DEREK Collaborative Group.Environ Health Perspect. 1996 Oct;104 Suppl 5(Suppl 5):1065-73. doi: 10.1289/ehp.96104s51065. Environ Health Perspect. 1996. PMID: 8933056 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical